welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Sulindac for Periampullary Polyps in FAP PatientsBACKGROUND : Gastro-duodenal polyps deve...
-
Food Fit for a Baby J-pouch: The Early Post-Proctocolectomy Diet (the newest fad diet)https://www.youtube.com/watch?v=ms8o1BBN...
-
Curcumin in Treating Patients With Familial Adenomatous PolyposisThis clinical trial studies curcumin in ...
-
Chemoprevention in Familial Adenomatous Polyposis: A review of the Concept of Chemoprevention and the Current Clini...Familial adenomatous polyposis (FAP) pre...
-
SCALEing F.A.P.: Impact of J-Pouch Surgeries on My Weighthttps://www.youtube.com/watch?v=Nz2p-KzD...
-
Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) is ...